04 · 21 proprietary layers
Layer 18 of 21 · Action and continuity
CostPath Treatment pathways and cost considerations.
Why it's needed
What treatment-related cost or pathway considerations can be surfaced?
What it draws on
3 of 8 evidence domains.
What it produces
Cost and pathway context with geography, date and assumptions stated.
Why it's essential
Layer 18 of 21.
1 · What it does
What CostPath does
Cost and access shape real treatment decisions. CostPath is intended to make treatment-pathway and cost considerations visible for discussion, with the geography, date and assumptions behind them stated.
2 · Scientific question
The question it addresses
What treatment-related cost or pathway considerations can be surfaced?
Intended function
Describe the sources and assumptions used to present cost and pathway information, if available.
3 · Data inputs and required context
What it draws on
- 06 Treatment exposure
- 08 Evidence ecosystem
- 07 Patient factors
The options under consideration and the cost sources in use.
4 · Scientific basis
The science behind it
Scientific basis
Treatment costs depend on location, provider, date, dosing and duration, and change frequently. Any cost information is an estimate under stated assumptions.
5 · Output and evidence sources
What it produces
Main output
Cost and pathway context with geography, date and assumptions stated.
Output type
- Evidence-linked interpretation. Connects a finding to published or curated evidence, which has a source and a date.
6 · Why it\u2019s essential
How it powers the Twin
Adds practical pathway context to the treatment-options and trial sections.
Report section
Capability
ExploreReview treatment-relevant evidence, resistance-related findings and potential trial matches.
7 · Why it\u2019s needed
What it changes — for doctors, patients and researchers
Patients & caregivers
Supports financial planning conversations; it is not a quotation.
Patient & Caregiver8 · Dependencies and limitations
Limitations
- Costs are time- and location-dependent.
9 · Review and uncertainty
How the output is handled
Output status
An AI-assisted analytical output presented as structured findings for clinician review. It becomes part of a report only after the treating oncologist has reviewed and signed it.
How uncertainty is communicated
Every figure is dated and states its geography and assumptions.
10 · Claim boundary
What this layer does not establish
It does not provide a quotation, confirm insurance coverage or guarantee availability.
The treating oncologist owns every decision. Every Twin report is reviewed and signed by the treating oncologist, then taken to KPCIRC's Molecular Tumour Board.
KPCIRC sign-off process